ARS PHARMACEUTICALS, INC

NASDAQ: SPRY (ARS Pharmaceuticals, Inc.)

Last update: 4 days ago, 8:40AM

3.89

0.08 (2.10%)

Previous Close 3.81
Volume 1,297,322
Price / Sales 3.10
Price / Book 24.24
52 Weeks Range
2.44 (-37%) — 13.15 (238%)
Profit Margin -16.11%
Operating Margin (TTM) -466.29%
Diluted EPS (TTM) -0.160
Quarterly Revenue Growth (YOY) 4,900.00%
Total Debt/Equity (MRQ) 30.33%
Current Ratio (MRQ) 11.00
Operating Cash Flow (TTM) -20.48 M
Levered Free Cash Flow (TTM) -9.60 M
Return on Assets (TTM) -6.10%
Return on Equity (TTM) -6.91%

AIStockmoo Score

-2.5
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
Return on Capital info NA
From our AI technical analysis of the chart. info NA
Downtrend over the past year. Far below its 52-week high. info
Price and its moving averages are lined up in a downtrend. Its main moving average is falling. Close to its falling moving average. Volume is heavier on up days. Below its long-term moving average, so not rated positive. info
Candle Patterns info NA
Below its medium-term trend line. info
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Insider Activity info NA
Institutions net -7.54% of shares in their latest 13F filings: 107 holders increased, 97 decreased (quarter to 30 Sep 2026). info
Short interest -18.2% from 31 Aug to 30 Oct 2026, 11.1 days to cover (FINRA). info
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Price is low against its 52-week average. Down over 5 years. info
Short-term trend up, medium and long-term down. Short-term decline easing. info
Price is near resistance. Levels trending up. info
Final Score -2.49
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock ARS Pharmaceuticals, Inc. Mixed Mixed

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SPRY - - - 24.24
TRML 1 B - - 4.76
OBIO - - - 57.25
VRDN - - - 7.26
VRCA - - - 15.60
TECH - 0.44% - 5.28

Select this tab to load the latest available analysis.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 16.93%
% Held by Institutions 80.28%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 91.55%

Positions Holders Shares
Increased 107 9,397,041
Decreased 97 16,447,542
New 38 2,967,760
Sold out 40 3,536,660

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 18,990,650 11.1
15 Oct 2026 19,819,885 12.6
30 Sep 2026 21,190,047 16.1
15 Sep 2026 23,073,209 15.5
31 Aug 2026 23,209,349 14.1
14 Aug 2026 22,952,291 11.0

FINRA short interest via Nasdaq, reported twice a month.

1 Positive 1 Negative 2 Neutral
Date Type Details
06 Nov 2026 Yahoo Finance ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...
ARS Pharmaceuticals Inc (SPRY) posted 42% year-over-year growth in neffy end-user demand and cut SG&A by over 40%, keeping it on track for cash flow breakeven by year-end 2027…
05 Nov 2026 Yahoo Finance ARS Pharmaceuticals Q3 Earnings Call Highlights
ARS Pharmaceuticals (NASDAQ:SPRY) reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow breakeven by the end of 2027. President and CEO Donn Casale said neffy’s share of the U.S. epinephrine ma…
05 Nov 2026 Yahoo Finance ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -5.88% and -11.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
05 Nov 2026 Yahoo Finance ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy® neffy U.S. market share reached 5% overall and 9% in field-targeted accounts, supporting the company’s updated targeted provider commercial strategyReduced SG&A spend reflected in Q3 operating…
29 Oct 2026 Yahoo Finance ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
28 Oct 2026 Yahoo Finance ARS Pharma to Report Third Quarter 2026 Financial Results
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and…
01 Sep 2026 Yahoo Finance ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in…
21 Aug 2026 Yahoo Finance ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share
On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale. He used it to lay out three priorities: sharper commercial targeting for neffy, tighter financial discipline, and a pipeline push into chronic spontaneous…
20 Aug 2026 Yahoo Finance Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 297% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the…

Technical Setup Medium

Trend order
Slope
Entry
Volume
Price and its moving averages are lined up in a downtrend. Its main moving average is falling. Close to its falling moving average. Volume is heavier on up days. Below its long-term moving average, so not rated positive.
Nearest support: 2.82 – 3.00 · moderate level
Nearest resistance: 3.72 – 3.90 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria